StockNews.AI
CVM
StockNews.AI
158 days

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

1. A JAMA study shows Multikine can treat ~70% of Head and Neck cancer patients. 2. This evidence strengthens the potential market position of CVM's Multikine treatment.

2m saved
Insight
Article

FAQ

Why Bullish?

The study’s findings support Multikine's efficacy, enhancing investor confidence. Historical positive trial results have led to increases in CVM's stock price.

How important is it?

The strong study results may affect investor interest and potential FDA discussions, influencing stock value.

Why Long Term?

If FDA approval follows, demand for Multikine may grow significantly over years. Previous FDA approvals in oncology have led to sustained stock price growth.

Related Companies

AMGNPFEJNJ
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Related News